Sugi Predict

Sugi Predict / Compounds / SCHEMBL6955366

SCHEMBL6955366

SCHEMBL6955366

CC(=O)c1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.71
▸ HPGD P15428 4/20 0.71
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ LMNA P02545 1/20 0.71
▸ NPC1 O15118 3/20 0.69
▸ SLC6A5 Q9Y345 4/20 0.69
▸ RAB9A P51151 2/20 0.68
▸ TP53 P04637 1/20 0.68
▸ ALOX15 P16050 1/20 0.68
▸ TSHR P16473 1/20 0.68
▸ MAPK1 P28482 1/20 0.68
▸ SLC6A9 P48067 7/20 0.66
▸ L3MBTL1 Q9Y468 2/20 0.60
▸ MEN1 O00255 1/20 0.58
▸ MAPT P10636 1/20 0.58
▸ HTT P42858 1/20 0.58
▸ KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3929509 0.88 SLC6A5 (0.86) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL2579603 0.86 HPGD (0.74) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL12176914 0.86 HPGD (0.70) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL1397520 0.85 HPGD (0.68) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL19210092 0.84 NPC1 (0.81) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL3925116 0.84 SLC6A5 (0.79) ALDH1A1HPGDSMN1; SMN2NPC1SLC6A5
SCHEMBL4093686 0.83 SMN1; SMN2 (0.61) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL17407220 0.83 ALDH1A1 (0.58) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL937021 0.83 MAPT (0.66) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL20702614 0.83 HPGD (0.64) ALDH1A1HPGDSMN1; SMN2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-06-06 — — US disclosed
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2024-02-13 — — US disclosed
EP-3661917-B1 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AG (DE) 2022-05-11 — — EP disclosed
EP-3661917-B1 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AG (DE) 2022-05-11 — — EP disclosed
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2020-08-06 — — US disclosed
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2020-08-06 — — US disclosed
EP-3661917-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER Bayer Aktiengesellschaft (DE) 2020-06-10 — — EP disclosed
WO-2019025554-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 — — WO disclosed
WO-2019025554-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 — — WO disclosed
EP-1075475-B1 HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION FUJISAWA PHARMACEUTICAL CO (JP) 2003-06-18 — — EP disclosed
US-20020132809-A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-09-19 — — US disclosed
EP-1075475-A1 HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-02-14 — — EP disclosed
WO-1999057114-A1 HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-11-11 — — WO disclosed
EP-0858453-A1 5-(ACETAMIDOMETHYL)-3-ARYLDIHYDROFURAN-2-ONE AND TETRAHYDROFURAN-2-ONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY AstraZeneca AB (SE) 1998-08-19 — — EP disclosed
WO-1997014690-A1 5-(ACETAMIDOMETHYL)-3-ARYLDIHYDROFURAN-2-ONE AND TETRAHYDROFURAN-2-ONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY ZENECA LIMITED (GB) 1997-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3A, PDE3B, PDE5A ALDH1A1 118/4885HPGD 71/4885SMN1; SMN2 3303/4885
US-20020132809-A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production NOS1, NOS3, NOS2 ALDH1A1 2145/4885HPGD 443/4885SMN1; SMN2 62/4885
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3B, PDE3A, PDE5A ALDH1A1 53/4885HPGD 272/4885SMN1; SMN2 3985/4885
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer PDE3B, PDE3A, PDE5A ALDH1A1 53/4885HPGD 272/4885SMN1; SMN2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.